Latest revenue
$0
as of 2026-03-31
Latest net income
$-272.6K
as of 2026-03-31
Net margin
—
as of 2026-03-31
Price · 5Y
Live market
delayed ≤15 min- Market cap
- $1.4M
- Enterprise value
- $1.4M
- P/E (trailing)
- —
- Forward P/E
- —
- P/B
- —
- Dividend yield
- 0.0%
- 52-wk high
- $0.18
- 52-wk low
- $0.01
- Beta
- —
- Shares out
- 170.4M
5-year trend
What this company does
Corporate Overview We are a U.S. holding company primarily operating through our wholly owned subsidiary, Platinum International Biotech Co., Ltd., a company organized under the laws of the Cayman Islands (“Platinum”). Platinum is not a Chinese operating company but a Cayman Islands holding company, which in turn operates in China through its subsidiaries and contractual arrangements with a variable interest entity (“VIE”), Yubo International Biotech (Beijing) Limited, a company organized under the laws of the People’s Republic of China and which is, through contractual arrangements with us, the Chinese operating company (“Yubo Beijing”). None of our Company, Platinum, or Platinum…
AI summary unavailable — showing raw filing excerpt
Generated from YBGJ's filing dated 2026-03-31
Key risks
Except for the historical information contained herein or incorporated by reference, this Annual Report and the information incorporated by reference herein contain forward-looking statements that involve risks and uncertainties. These statements include projections about our accounting and finances, plans and objectives for the future, future operating and economic performance and other statements regarding future performance. These statements are not guarantees of future performance or events. Our actual results could differ materially from those discussed in this report. Factors that could cause or contribute to these differences include, but are not limited to, those discussed in this…
AI summary unavailable — showing raw filing excerpt
Generated from YBGJ's filing dated 2026-03-31
Profitability
Gross margin
66.1%
13.4%Operating margin
-9614.6%
81.2%Net margin
-8736.7%
84.7%Return on equity
55.2%
4.6%Return on assets
-127.4%
1.3%Leverage
Debt / equity
-1.43×
1.0%Debt / assets
330.7%
2.4%Earnings tracker
| Quarter | Revenue | YoY | Net income | YoY | Net margin |
|---|---|---|---|---|---|
Q1 2026 2026-03-31 | $0 | — | $-272.6K | +37.4% | — |
Q4 2025 2025-12-31 | $12.4K | +68727.8% | $-103.1K | +77.4% | -834.9% |
Q3 2025 2025-09-30 | $0 | — | $-310.2K | +50.1% | — |
Q2 2025 2025-06-30 | $0 | — | $-230.3K | +56.3% | — |
Q1 2025 2025-03-31 | $0 | -100.0% | $-435.6K | -15.5% | — |
Q4 2024 2024-12-31 | $-18 | — | $-455.9K | — | — |
Q3 2024 2024-09-30 | $0 | -100.0% | $-621.1K | -9968.9% | — |
Q2 2024 2024-06-30 | $0 | -100.0% | $-527.5K | -43.6% | — |
Year-over-year change vs the same fiscal quarter one year prior. Revenue + net income sourced from SEC 10-Q / 10-K filings — no analyst-consensus dependency.
Industry trend
Electromedical & Electrotherapeutic Apparatus · SIC 3845
Your notes
Keep private notes on YBGJ — thesis, target price, catalysts to watch.
Visible only to you. Never shared. Never used to train AI.
Insider activity
Insider buying
$0
Insider selling
$0
Net activity
+$0
Distinct insiders
0
Open-market trades over the last 365 days.
Recent transactions
| Date | Insider | Type | Shares | Price | Value |
|---|
Source: SEC Form 4 filings. Officers, directors, and 10%+ owners must disclose share transactions within two business days. RSU grants and tax-withholding rows are excluded by default — compensation activity is not a trading signal.
Who owns YBGJ
No institutional holdings on file for YBGJ yet.
Source: SEC Form 13F-HR. Updated quarterly (45-day filing lag).
Top questions investors are asking
Coming once YBGJ's latest filing finishes processing.